OBJECTIVES: The aim of this study is to develop and validate a hand-foot syndrome-specific quality of life scale to be able to measure the impact of the condition on patients and to be able to assess the value of certain specific treatments in this indication. METHODS: Forty-four patients were included during clinical consultation. RESULTS: A total of 61.91% of patients declared having their first episode of HSFR.  The mean age was 56.5 years and the population was represented by 75% of female. A total of 2.27%, 29.55%, 38.64% and 29.55% of patients graded 0, 1, 2, 3 in the disease severity; 14.63% of patients have their HFSR located on the hands, 24.39% on feet, 60.98% on both hands and feet.  The mean global score of the HFS 14 questionnaire is 37.63 (2-100). The mean score in grade 1 patients is 16.68, 41.18 in grade 2 patients, 53.09 in grade 3 patients. There is a significant difference between these 3 mean scores (p<0.0001).  The HFS 14 score is positively and significantly correlated to the DLQI and the Skindex-16 scores. The correlation coefficient between the HFS 14 and the DLQI questionnaires is 0.71324 (p<0.0001). The correlation coefficient between the HFS 14 and the Skindex16 questionnaires is 0.7347 (p<0.0001).  The HFS 14 score is negatively correlated with the SF-12 score. The correlation coefficient is significantly different from 0 concerning physical dimension (p=0.0027). The correlation coefficient is not significantly different from 0 concerning the mental dimension. The p-value is 0.4457.The HFS 14 score is positively and significantly correlated to the pain measured by the visual analogue scale (p<0.0001). The correlation is estimated 0.68142. CONCLUSIONS: The HFS 14 (or short version) meets requirements of QoL scale and is easy to use. The questionnaire is able to assess the clinical efficacy of new specific treatments developed for HFSR.